Genfit SA
(NASDAQ : GNFT)

( )
GNFT PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.45%98.560.0%$1438.14m
BIIBBiogen, Inc. -0.36%242.511.7%$630.38m
AMGNAmgen, Inc. -0.79%220.461.3%$568.17m
GILDGilead Sciences, Inc. 0.60%60.251.0%$535.76m
VRTXVertex Pharmaceuticals, Inc. -0.63%216.501.9%$470.81m
REGNRegeneron Pharmaceuticals, Inc. -3.34%506.102.7%$447.76m
BNTXBioNTech SE -4.35%101.870.0%$424.45m
ILMNIllumina, Inc. 1.25%305.633.5%$377.98m
NVAXNovavax, Inc. 1.44%95.3392.9%$339.05m
EXASEXACT Sciences Corp. -2.72%117.2619.6%$289.27m
MGENMiragen Therapeutics, Inc. -4.62%16.500.7%$248.55m
SRRKScholar Rock Holding Corp. 3.14%42.700.0%$242.63m
APVOAptevo Therapeutics, Inc. -3.58%43.9218.3%$210.20m
SGENSeagen Inc. -2.05%164.635.8%$167.34m
ALXNAlexion Pharmaceuticals, Inc. 0.41%123.112.0%$161.56m

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.